Cargando…
Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia
BACKGROUND: Acute myeloid leukemia (AML) with antecedent hematological disease (s-AML) and treatment-related AML (t-AML) predicts poor prognosis. Intensive treatment protocols of those high-risk patients should consider allogeneic stem cell transplantation (allo-HSCT) in first complete remission (CR...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114033/ https://www.ncbi.nlm.nih.gov/pubmed/34297206 http://dx.doi.org/10.1007/s00432-021-03733-0 |
_version_ | 1784709696854163456 |
---|---|
author | Fleischmann, Maximilian Schnetzke, Ulf Frietsch, Jochen J. Sayer, Herbert G. Schrenk, Karin Hammersen, Jakob Glaser, Anita Hilgendorf, Inken Hochhaus, Andreas Scholl, Sebastian |
author_facet | Fleischmann, Maximilian Schnetzke, Ulf Frietsch, Jochen J. Sayer, Herbert G. Schrenk, Karin Hammersen, Jakob Glaser, Anita Hilgendorf, Inken Hochhaus, Andreas Scholl, Sebastian |
author_sort | Fleischmann, Maximilian |
collection | PubMed |
description | BACKGROUND: Acute myeloid leukemia (AML) with antecedent hematological disease (s-AML) and treatment-related AML (t-AML) predicts poor prognosis. Intensive treatment protocols of those high-risk patients should consider allogeneic stem cell transplantation (allo-HSCT) in first complete remission (CR). Despite allo-HSCT, relapse rate remains high. Induction chemotherapy with liposomal cytarabine and daunorubicin (CPX-351) has been approved for patients with AML with myeloid-related changes (AML-MRC) or t-AML based on improved survival and remission rates compared to standard 7 + 3 induction. PATIENTS AND METHODS: 110 patients with newly diagnosed s-AML or t-AML at a university hospital were analyzed retrospectively. Median age was 62 years (24–77 years). A total of 65 patients with s-AML after MDS (59%) and 23 patients (20.9%) with t-AML were included. Induction chemotherapy consisted of intermediate-dosed cytarabine (ID-AraC) in combination with idarubicin (patients up to 60 years) or mitoxantrone (patients over 60 years). In patients subsequently undergoing allo-HSCT, reduced conditioning regimens (RIC) were applied prior to transplantation in 47 of 62 patients (76%). RESULTS: Induction chemotherapy with ID-AraC resulted in an overall response rate of 83% including complete remission (CR/CRi) in 69 patients (63%) with a low rate of early death (2.7%). Most relevant non-hematologic toxicity consisted of infectious complications including sepsis with need of intensive care treatment in five patients (4.5%) and proven or probable invasive fungal disease in eight patients (7.2%). Relapse-free survival (RFS), event-free survival (EFS) and overall survival (OS) of the whole cohort were 19 months (0–167), 10 months (0–234) and 15 months (0–234), respectively (p < 0.0001). A significant improvement of OS was observed in patients who underwent allo-HSCT compared to those without subsequent allo-HSCT: 9 vs. 46 months, p < 0.0001. Rate of transplantation-related mortality (TRM) in the early phase post allo-HSCT was low (0.9% at day 30 and 1.8% at day 90, respectively). RIC conditioning results in OS rate of 60% after 60 months post allo-HSCT (median OS not reached). CONCLUSION: S-AML and t-AML patients receiving induction chemotherapy with intermediate-dosed cytarabine showed satisfactory response rate and consolidation therapy with allo-HSCT after full or reduced-intensity conditioning further improved survival in these patients with similar outcome as reported for CPX-351. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00432-021-03733-0. |
format | Online Article Text |
id | pubmed-9114033 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-91140332022-05-19 Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia Fleischmann, Maximilian Schnetzke, Ulf Frietsch, Jochen J. Sayer, Herbert G. Schrenk, Karin Hammersen, Jakob Glaser, Anita Hilgendorf, Inken Hochhaus, Andreas Scholl, Sebastian J Cancer Res Clin Oncol Original Article – Clinical Oncology BACKGROUND: Acute myeloid leukemia (AML) with antecedent hematological disease (s-AML) and treatment-related AML (t-AML) predicts poor prognosis. Intensive treatment protocols of those high-risk patients should consider allogeneic stem cell transplantation (allo-HSCT) in first complete remission (CR). Despite allo-HSCT, relapse rate remains high. Induction chemotherapy with liposomal cytarabine and daunorubicin (CPX-351) has been approved for patients with AML with myeloid-related changes (AML-MRC) or t-AML based on improved survival and remission rates compared to standard 7 + 3 induction. PATIENTS AND METHODS: 110 patients with newly diagnosed s-AML or t-AML at a university hospital were analyzed retrospectively. Median age was 62 years (24–77 years). A total of 65 patients with s-AML after MDS (59%) and 23 patients (20.9%) with t-AML were included. Induction chemotherapy consisted of intermediate-dosed cytarabine (ID-AraC) in combination with idarubicin (patients up to 60 years) or mitoxantrone (patients over 60 years). In patients subsequently undergoing allo-HSCT, reduced conditioning regimens (RIC) were applied prior to transplantation in 47 of 62 patients (76%). RESULTS: Induction chemotherapy with ID-AraC resulted in an overall response rate of 83% including complete remission (CR/CRi) in 69 patients (63%) with a low rate of early death (2.7%). Most relevant non-hematologic toxicity consisted of infectious complications including sepsis with need of intensive care treatment in five patients (4.5%) and proven or probable invasive fungal disease in eight patients (7.2%). Relapse-free survival (RFS), event-free survival (EFS) and overall survival (OS) of the whole cohort were 19 months (0–167), 10 months (0–234) and 15 months (0–234), respectively (p < 0.0001). A significant improvement of OS was observed in patients who underwent allo-HSCT compared to those without subsequent allo-HSCT: 9 vs. 46 months, p < 0.0001. Rate of transplantation-related mortality (TRM) in the early phase post allo-HSCT was low (0.9% at day 30 and 1.8% at day 90, respectively). RIC conditioning results in OS rate of 60% after 60 months post allo-HSCT (median OS not reached). CONCLUSION: S-AML and t-AML patients receiving induction chemotherapy with intermediate-dosed cytarabine showed satisfactory response rate and consolidation therapy with allo-HSCT after full or reduced-intensity conditioning further improved survival in these patients with similar outcome as reported for CPX-351. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00432-021-03733-0. Springer Berlin Heidelberg 2021-07-23 2022 /pmc/articles/PMC9114033/ /pubmed/34297206 http://dx.doi.org/10.1007/s00432-021-03733-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article – Clinical Oncology Fleischmann, Maximilian Schnetzke, Ulf Frietsch, Jochen J. Sayer, Herbert G. Schrenk, Karin Hammersen, Jakob Glaser, Anita Hilgendorf, Inken Hochhaus, Andreas Scholl, Sebastian Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia |
title | Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia |
title_full | Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia |
title_fullStr | Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia |
title_full_unstemmed | Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia |
title_short | Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia |
title_sort | impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia |
topic | Original Article – Clinical Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114033/ https://www.ncbi.nlm.nih.gov/pubmed/34297206 http://dx.doi.org/10.1007/s00432-021-03733-0 |
work_keys_str_mv | AT fleischmannmaximilian impactofinductionchemotherapywithintermediatedosedcytarabineandsubsequentallogeneicstemcelltransplantationontheoutcomeofhighriskacutemyeloidleukemia AT schnetzkeulf impactofinductionchemotherapywithintermediatedosedcytarabineandsubsequentallogeneicstemcelltransplantationontheoutcomeofhighriskacutemyeloidleukemia AT frietschjochenj impactofinductionchemotherapywithintermediatedosedcytarabineandsubsequentallogeneicstemcelltransplantationontheoutcomeofhighriskacutemyeloidleukemia AT sayerherbertg impactofinductionchemotherapywithintermediatedosedcytarabineandsubsequentallogeneicstemcelltransplantationontheoutcomeofhighriskacutemyeloidleukemia AT schrenkkarin impactofinductionchemotherapywithintermediatedosedcytarabineandsubsequentallogeneicstemcelltransplantationontheoutcomeofhighriskacutemyeloidleukemia AT hammersenjakob impactofinductionchemotherapywithintermediatedosedcytarabineandsubsequentallogeneicstemcelltransplantationontheoutcomeofhighriskacutemyeloidleukemia AT glaseranita impactofinductionchemotherapywithintermediatedosedcytarabineandsubsequentallogeneicstemcelltransplantationontheoutcomeofhighriskacutemyeloidleukemia AT hilgendorfinken impactofinductionchemotherapywithintermediatedosedcytarabineandsubsequentallogeneicstemcelltransplantationontheoutcomeofhighriskacutemyeloidleukemia AT hochhausandreas impactofinductionchemotherapywithintermediatedosedcytarabineandsubsequentallogeneicstemcelltransplantationontheoutcomeofhighriskacutemyeloidleukemia AT schollsebastian impactofinductionchemotherapywithintermediatedosedcytarabineandsubsequentallogeneicstemcelltransplantationontheoutcomeofhighriskacutemyeloidleukemia |